Milestone Scientific Reports Year-End 2024 Financial Results and Reports Strong Outlook for 2025
Milestone Scientific (NYSE: MLSS) reported financial results for 2024, showing revenue of $8.6 million, down from $9.8 million in 2023. Despite the revenue decline, the company highlighted positive developments including Medicare reimbursement expansion for its CompuFlo® Epidural System across multiple U.S. states and a Federal Supply Schedule contract.
The company's U.S. e-commerce platform for dental products generated $5.1 million in revenue, up from $4.8 million in 2023. International revenue decreased to $3.4 million. Gross profit was $6.4 million, down from $6.8 million in 2023. Operating loss improved to $6.8 million from $7.1 million, while net loss decreased to $4.7 million ($0.06 per share) from $6.9 million ($0.10 per share) in 2023.
The company ended 2024 with $3.3 million in cash, $5.5 million in working capital, and no debt, while reporting strong Q1 2025 initial performance and positive outlook.
Milestone Scientific (NYSE: MLSS) ha riportato i risultati finanziari per il 2024, con un fatturato di 8,6 milioni di dollari, in calo rispetto ai 9,8 milioni del 2023. Nonostante la diminuzione del fatturato, l'azienda ha evidenziato sviluppi positivi, tra cui l'espansione del rimborso Medicare per il suo sistema CompuFlo® Epidural in diversi stati degli Stati Uniti e un contratto nel Federal Supply Schedule.
La piattaforma di e-commerce statunitense per prodotti dentali ha generato un fatturato di 5,1 milioni di dollari, in aumento rispetto ai 4,8 milioni del 2023. Il fatturato internazionale è diminuito a 3,4 milioni di dollari. Il profitto lordo è stato di 6,4 milioni, in calo rispetto ai 6,8 milioni del 2023. La perdita operativa è migliorata a 6,8 milioni di dollari rispetto a 7,1 milioni, mentre la perdita netta è scesa a 4,7 milioni di dollari (0,06 dollari per azione) rispetto a 6,9 milioni (0,10 dollari per azione) nel 2023.
L'azienda ha chiuso il 2024 con 3,3 milioni di dollari in liquidità, 5,5 milioni di capitale circolante e nessun debito, riportando inoltre un forte inizio del primo trimestre 2025 e una prospettiva positiva.
Milestone Scientific (NYSE: MLSS) informó resultados financieros para 2024, mostrando ingresos de $8.6 millones, una disminución respecto a los $9.8 millones en 2023. A pesar de la caída en ingresos, la compañía destacó desarrollos positivos, incluyendo la expansión del reembolso de Medicare para su sistema CompuFlo® Epidural en varios estados de EE.UU. y un contrato en el Federal Supply Schedule.
La plataforma de comercio electrónico estadounidense para productos dentales generó ingresos de $5.1 millones, un aumento comparado con los $4.8 millones de 2023. Los ingresos internacionales disminuyeron a $3.4 millones. La ganancia bruta fue de $6.4 millones, inferior a los $6.8 millones de 2023. La pérdida operativa mejoró a $6.8 millones desde $7.1 millones, mientras que la pérdida neta se redujo a $4.7 millones ($0.06 por acción) desde $6.9 millones ($0.10 por acción) en 2023.
La compañía terminó 2024 con $3.3 millones en efectivo, $5.5 millones en capital de trabajo y sin deuda, además de reportar un sólido desempeño inicial en el primer trimestre de 2025 y una perspectiva positiva.
Milestone Scientific (NYSE: MLSS)는 2024년 재무 실적을 발표하며 매출액이 860만 달러로 2023년 980만 달러에서 감소했다고 밝혔습니다. 매출 감소에도 불구하고 회사는 미국 여러 주에서 CompuFlo® Epidural 시스템에 대한 Medicare 환급 확대와 연방 공급 일정 계약 등 긍정적인 발전을 강조했습니다.
미국 내 치과 제품 전자상거래 플랫폼은 510만 달러의 매출을 기록해 2023년 480만 달러에서 증가했습니다. 국제 매출은 340만 달러로 감소했습니다. 총이익은 640만 달러로 2023년 680만 달러에서 줄었으며, 영업 손실은 710만 달러에서 680만 달러로 개선되었고, 순손실은 690만 달러에서 470만 달러(주당 0.06달러)로 감소했습니다.
회사는 2024년을 330만 달러 현금, 550만 달러 운전자본, 무부채 상태로 마감했으며, 2025년 1분기 초기 실적이 견조하고 긍정적인 전망을 보고했습니다.
Milestone Scientific (NYSE : MLSS) a publié ses résultats financiers pour 2024, affichant un chiffre d'affaires de 8,6 millions de dollars, en baisse par rapport à 9,8 millions en 2023. Malgré cette baisse, la société a souligné des avancées positives, notamment l'extension du remboursement Medicare pour son système CompuFlo® Epidural dans plusieurs États américains et un contrat au Federal Supply Schedule.
La plateforme e-commerce américaine pour les produits dentaires a généré un chiffre d'affaires de 5,1 millions de dollars, en hausse par rapport à 4,8 millions en 2023. Les revenus internationaux ont diminué à 3,4 millions de dollars. La marge brute s'est élevée à 6,4 millions, en baisse par rapport à 6,8 millions en 2023. La perte d'exploitation s'est améliorée à 6,8 millions de dollars contre 7,1 millions, tandis que la perte nette a diminué à 4,7 millions de dollars (0,06 dollar par action) contre 6,9 millions (0,10 dollar par action) en 2023.
La société a clôturé 2024 avec 3,3 millions de dollars en liquidités, 5,5 millions de fonds de roulement et aucune dette, tout en rapportant un bon début de premier trimestre 2025 et des perspectives positives.
Milestone Scientific (NYSE: MLSS) meldete die Finanzergebnisse für 2024 mit einem Umsatz von 8,6 Millionen US-Dollar, was einem Rückgang gegenüber 9,8 Millionen US-Dollar im Jahr 2023 entspricht. Trotz des Umsatzrückgangs hob das Unternehmen positive Entwicklungen hervor, darunter die Erweiterung der Medicare-Erstattung für sein CompuFlo® Epidural-System in mehreren US-Bundesstaaten sowie einen Vertrag im Federal Supply Schedule.
Die US-E-Commerce-Plattform für Zahnprodukte erzielte einen Umsatz von 5,1 Millionen US-Dollar, gegenüber 4,8 Millionen im Jahr 2023. Die internationalen Einnahmen sanken auf 3,4 Millionen US-Dollar. Der Bruttogewinn betrug 6,4 Millionen, ein Rückgang von 6,8 Millionen im Jahr 2023. Der Betriebsverlust verbesserte sich auf 6,8 Millionen US-Dollar gegenüber 7,1 Millionen, während der Nettoverlust auf 4,7 Millionen US-Dollar (0,06 US-Dollar je Aktie) von 6,9 Millionen (0,10 US-Dollar je Aktie) im Jahr 2023 sank.
Das Unternehmen schloss das Jahr 2024 mit 3,3 Millionen US-Dollar in bar, 5,5 Millionen im Working Capital und ohne Schulden ab und berichtete zudem von einem starken Start ins erste Quartal 2025 sowie einer positiven Prognose.
- Medicare reimbursement expansion across multiple U.S. states for CompuFlo System
- Federal Supply Schedule (FSS) contract award for federal medical facilities
- E-commerce revenue growth to $5.1M from $4.8M YoY
- Improved operating loss to $6.8M from $7.1M YoY
- Reduced net loss per share to $0.06 from $0.10 YoY
- Debt-free balance sheet with $3.3M cash position
- Total revenue declined 12.2% to $8.6M from $9.8M YoY
- International revenue decreased by $756,000
- Gross profit declined to $6.4M from $6.8M YoY
- Loss of Henry Schein distribution revenue ($179,000 in 2023 to $0 in 2024)
- U.S. distributor revenue dropped significantly from $485,000 to $9,000
Insights
Milestone Scientific's 2024 results reveal a strategic transition year. While revenue dropped 12.2% to $8.6 million from $9.8 million in 2023, the company has strategically pivoted toward higher-margin business models. The direct-to-consumer e-commerce platform for dental products grew to $5.1 million from $4.8 million, demonstrating early success of this shift away from traditional distribution.
Despite lower revenue, MLSS improved its financial efficiency, narrowing operating losses to $6.8 million from $7.1 million and reducing net losses to $4.7 million ($0.06 per share) from $6.9 million ($0.10 per share). The company maintains a stable balance sheet with $3.3 million cash, $5.5 million working capital, and zero debt.
The most significant development is the expanded Medicare reimbursement infrastructure for the CompuFlo® Epidural System, with favorable payment rates now covering 13 states. This critical milestone substantially expands the addressable market. The Federal Supply Schedule contract further opens access to federal healthcare facilities, creating an entirely new growth avenue.
The Q1 2025 client acquisitions across pain management clinics and ambulatory surgery centers indicate the reimbursement framework is beginning to drive adoption. With strong dental segment leadership (95+ million injections administered) and improving medical segment positioning, MLSS appears to be approaching an inflection point after completing necessary strategic realignments.
Reports expansion of CompuFlo® Epidural System across additional
pain management clinics and ambulatory surgery centers following
Medicare price assignment in multiple U.S. states
ROSELAND, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2024.
Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, stated, “While 2024 was a year of transition for Milestone Scientific, we laid the foundation for a strong rebound in 2025. We focused intently on streamlining operations and aligning our cost structure to support sustainable growth. The initial performance in Q1 2025 has been highly encouraging, and we are optimistic about continued traction in both the dental and medical segments.”
“On the medical side, we made substantial progress in establishing the reimbursement infrastructure to drive adoption of our CompuFlo® Epidural System. In 2024, First Coast Service Options (FCSO) and Novitas Solutions, two Jurisdictional Medicare Administrative Contractors (JMACs), assigned favorable Medicare Part B physician payment rates for our technology under CPT code 0777T. These assignments now cover providers in Florida, New Jersey, Texas, Pennsylvania, Maryland, Delaware, Washington D.C., Colorado, Louisiana, Mississippi, New Mexico, Oklahoma, and Arkansas. These Medicare pricing decisions have significantly expanded our addressable market and positioned us to scale adoption. Importantly, we are actively pursuing reimbursement approvals with additional JMACs to further our national expansion and make the CompuFlo system more widely accessible across the U.S.”
“Additionally, we were awarded a contract for the Federal Supply Schedule (FSS), enabling federal medical facilities to purchase CompuFlo. We are currently working with key stakeholders to drive adoption of the CompuFlo® Epidural System and improve patient outcomes within the U.S. Department of Veterans Affairs (VA), Department of Defense (DoD), Indian Health Service (IHS), and other federal healthcare systems.”
“Beyond our federal initiatives, we are seeing strong commercial traction in the private sector, highlighted by new rollouts during Q1 2025 at Advanced Spine and Pain Management, Pain Doctors Medical LLC, and InfiniSurg, LLC. These recent adoptions demonstrate growing clinical confidence in the CompuFlo system and broader market acceptance of our technology across pain management clinics and ambulatory surgery centers. Our strategic partnership with Axial Biologics has also continued to enhance our distribution footprint in key U.S. markets.”
“In the dental segment, our STA Single Tooth Anesthesia System remains the global leader in computer-controlled local anesthetic delivery, with over 95 million injections administered to date. In 2024, we further leveraged this leadership through the expansion of our direct-to-consumer e-commerce platform, which is already delivering improved margins and increased customer engagement.”
Mr. Goldman concluded, “We believe we are in the early stages of unlocking the true commercial potential of our core technology. The clinical response has been exceptionally positive, and we are well-positioned to capitalize on the growth opportunities ahead. Q1 2025 results thus far reinforce our confidence, and we are highly encouraged by the outlook for the balance of the year on both the dental and medical fronts.”
Financial Results for the Year Ended December 31, 2024
For the years ended December 31, 2024 and 2023, revenue was approximately
The Company recorded no revenue from Henry Schein in 2024, compared to approximately
International revenue was approximately
Gross profit for 2024 was
Operating loss for 2024 was
As of December 31, 2024, the Company had cash of
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2024. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
(tables follow)
| MILESTONE SCIENTIFIC AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| December 31, 2024 | December 31, 2023 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,258,058 | $ | 2,977,713 | ||||
| Marketable securities | - | 2,976,573 | ||||||
| Accounts receivable, net of allowance for credit losses of | 475,376 | 312,664 | ||||||
| Prepaid expenses and other current assets | 564,645 | 517,785 | ||||||
| Inventories | 3,713,215 | 2,638,186 | ||||||
| Advances on contracts | 1,275,260 | 1,371,548 | ||||||
| Total current assets | 9,286,554 | 10,794,469 | ||||||
| Furniture, fixtures and equipment, net | 12,921 | 10,024 | ||||||
| Intangibles, net | 148,404 | 178,636 | ||||||
| Right of use assets finance lease | 67,201 | 8,998 | ||||||
| Right of use assets operating lease | 257,842 | 355,235 | ||||||
| Other assets | 24,150 | 24,150 | ||||||
| Total assets | $ | 9,797,072 | $ | 11,371,512 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,021,393 | $ | 689,604 | ||||
| Accounts payable, related party | 493,313 | 410,512 | ||||||
| Accrued expenses and other payables | 1,796,319 | 1,511,717 | ||||||
| Accrued expenses, related party | 304,293 | 137,189 | ||||||
| Accrued liabilities noncontrolling interest | - | 214,000 | ||||||
| Current portion of finance lease liabilities | 12,530 | 10,264 | ||||||
| Current portion of operating lease liabilities | 116,279 | 103,427 | ||||||
| Total current liabilities | 3,744,127 | 3,076,713 | ||||||
| Non-current portion of finance lease liabilities | 54,672 | 434 | ||||||
| Non-current portion of operating lease liabilities | 165,573 | 281,853 | ||||||
| Total liabilities | $ | 3,964,372 | $ | 3,359,000 | ||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity | ||||||||
| Common stock, par value | 78,048 | 75,881 | ||||||
| Additional paid in capital | 134,719,274 | 132,187,656 | ||||||
| Accumulated deficit | (128,053,106 | ) | (123,339,509 | ) | ||||
| Treasury stock, at cost, 33,333 shares | (911,516 | ) | (911,516 | ) | ||||
| Total Milestone Scientific, Inc. stockholders' equity | 5,832,700 | 8,012,512 | ||||||
| Total liabilities and stockholders’ equity | $ | 9,797,072 | $ | 11,371,512 | ||||
| MILESTONE SCIENTIFIC AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR YEARS ENDED DECEMBER 31, | ||||||||
| 2024 | 2023 | |||||||
| Product sales, net | $ | 8,629,928 | $ | 9,827,444 | ||||
| Cost of products sold | 2,195,340 | 3,034,832 | ||||||
| Gross profit | 6,434,588 | 6,792,612 | ||||||
| Selling, general and administrative expenses | 12,295,330 | 13,135,796 | ||||||
| Research and development expenses | 858,767 | 701,378 | ||||||
| Depreciation and amortization expense | 37,448 | 61,912 | ||||||
| Total operating expenses | 13,191,545 | 13,899,086 | ||||||
| Loss from operations | (6,756,957 | ) | (7,106,474 | ) | ||||
| Interest income | 60,265 | 125,527 | ||||||
| Gain on sale of net operating losses | 1,983,095 | - | ||||||
| Loss before provision for income taxes | (4,713,597 | ) | (6,980,947 | ) | ||||
| Net loss | (4,713,597 | ) | (6,980,947 | ) | ||||
| Net loss attributable to noncontrolling interests | - | (51,843 | ) | |||||
| Net loss attributable to Milestone Scientific Inc. | $ | (4,713,597 | ) | $ | (6,929,104 | ) | ||
| Net loss per share applicable to common stockholders— | ||||||||
| Basic and Diluted | (0.06 | ) | (0.10 | ) | ||||
| Weighted average shares outstanding and to be issued— | ||||||||
| Basic and diluted | 79,791,188 | 72,775,781 | ||||||
FAQ
What was Milestone Scientific's (MLSS) revenue for 2024 compared to 2023?
How much revenue did MLSS generate from its U.S. e-commerce platform in 2024?
What was MLSS's net loss per share in 2024?
Which states now have Medicare coverage for MLSS's CompuFlo Epidural System?
What is MLSS's cash position at the end of 2024?
